Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Febrile Neutropenia × pegylated granulocyte colony-stimulating factor × Clear all

Phase

Phase 2 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Recurrence 1 Neutropenia 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Hodgkin Disease 1 Febrile Neutropenia 1 Esophageal Neoplasms 1 Breast Neoplasms 1

Interventions

pegfilgrastim 2 pegylated granulocyte colony-stimulating factor 1 Vancomycin 1 TKN732 1 Linezolid 1 Levofloxacin 1 Filgrastim 1 Bevacizumab 1 Amoxicillin-Potassium Clavulanate Combination 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04466137 2022-02-09

Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy

Xiamen Amoytop Biotech Co., Ltd.

Phase 3 Completed

Classical hematology

Neutropenia, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡